Detail of the clinical trial
| Title of the trial | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies |
|---|---|
| EudraCT number | 2019-003444-72 |
| Protocol number | MK-6482-005 |
| Sponsor | Merck Sharp & Dohme LLC, 126 East Lincoln Ave.,P.O.BOX 2000,Rahway, New Jersey 07065, United States of America |
| Indications | Oncology |
| Diagnosis | Renal Cell Carcinoma |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2020 |
| Date of approval by Institute (SÚKL) | 20.5.2020 |
| Date of approval by EC | 30.4.2020 |
| Date of initiation CT in ČR | 27.7.2020 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Fakultní nemocnice Hradec Králové,Klinika onkologie a radioterapie,Sokolská 581, Hradec Králové,50005 Masarykův onkologický ústav, Klinika komplexní onkologické péče,Žlutý kopec 7 ,Brno,65653 Fakultní nemocnice Olomouc,Onkologická klinika, I. P. Pavlova 6,Olomouc, 77520 Fakultní nemocnice Ostrava ,Klinika onkologická ,17.listopadu 1790,Ostrava-Poruba,70852 Fakultní nemocnice Královské Vinohrady,Klinika radioterapie a onkologie,Šrobárova 50,Praha 10,100 34 |
cz